+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Cancer Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application- Product Image
Liver Cancer Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application- Product Image
New

Liver Cancer Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

  • PDF Icon

    Report

  • 87 Pages
  • May 2025
  • Region: Global
  • Prof Research
  • ID: 5643967
Description Jump to:
Liver cancer drugs encompass targeted therapies, immunotherapies, and chemotherapies to manage hepatocellular carcinoma (HCC), with 900,000 new cases in 2020, 70% in Asia due to hepatitis B and C prevalence. The market is driven by rising liver cancer incidence, with 10% of 325 million hepatitis patients progressing to HCC, and breakthroughs in immunotherapy, such as atezolizumab plus bevacizumab, extending median survival to 19 months. Early diagnosis initiatives, aging populations, and high viral hepatitis burden fuel demand. The global liver cancer drug market is estimated at USD 2.5-4.0 billion in 2025, with a CAGR of 15%-20% through 2030.

Regional Market Trends

  • North America: The U.S. leads with advanced immunotherapy adoption, while Canada focuses on hepatitis screening.
  • Europe: Germany, France, and the UK drive growth with robust oncology programs.
  • Asia Pacific: China and India see high demand due to hepatitis prevalence, with Japan emphasizing targeted therapies.
  • Rest of the World: Brazil expands HCC treatment access, while Africa addresses hepatitis-related cancers.

Application Analysis

  • Targeted Therapy: Expected growth of 15.5%-20.5%, driven by sorafenib and lenvatinib. Trends focus on multi-kinase inhibitors.
  • Immunotherapy: Projected growth of 16.0%-21.0%, favored for long-term survival. Advances emphasize PD-1/PD-L1 inhibitors.
  • Chemotherapy: Anticipated growth of 14.0%-19.0%, used in advanced cases. Trends highlight combination regimens.
  • Others: Expected growth of 13.5%-18.5%, covering ablation therapies. Developments prioritize minimally invasive options.

Key Market Players

  • Bayer: Offers sorafenib for HCC.
  • Roche: Develops atezolizumab for immunotherapy.
  • Merck: Provides PD-1 inhibitors for liver cancer.
  • Bristol-Myers Squibb: Focuses on immunotherapy combinations.
  • Eisai: Specializes in lenvatinib for targeted therapy.

Porter’s Five Forces Analysis

  • Threat of New Entrants: Low, due to high R&D costs and regulatory barriers.
  • Threat of Substitutes: Moderate, with surgical options competing, but drugs are primary for advanced HCC.
  • Bargaining Power of Buyers: Moderate, as hospitals seek cost-effective therapies, but specialized drugs limit choices.
  • Bargaining Power of Suppliers: Low, with multiple providers of active ingredients.
  • Competitive Rivalry: High, with players competing on efficacy and survival outcomes.

Market Opportunities and Challenges

Opportunities:

  • Addressing liver cancer, with 900,000 new cases in 2020.
  • Leveraging immunotherapy, extending survival to 19 months.
  • Managing hepatitis, affecting 325 million people.
  • Supporting early diagnosis initiatives for HCC.
  • Meeting demand in Asia, with 70% of cases.
  • Expanding access to generics in low-income regions.

Challenges:

  • High costs of immunotherapies limiting access.
  • Regulatory delays for novel drugs.
  • Limited screening infrastructure in developing regions.
  • Competition from ablation and surgical treatments.
  • Side effects requiring patient monitoring.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Liver Cancer Drug Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Liver Cancer Drug Market in North America (2020-2030)
8.1 Liver Cancer Drug Market Size
8.2 Liver Cancer Drug Market by End Use
8.3 Competition by Players/Suppliers
8.4 Liver Cancer Drug Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Liver Cancer Drug Market in South America (2020-2030)
9.1 Liver Cancer Drug Market Size
9.2 Liver Cancer Drug Market by End Use
9.3 Competition by Players/Suppliers
9.4 Liver Cancer Drug Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Liver Cancer Drug Market in Asia & Pacific (2020-2030)
10.1 Liver Cancer Drug Market Size
10.2 Liver Cancer Drug Market by End Use
10.3 Competition by Players/Suppliers
10.4 Liver Cancer Drug Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Liver Cancer Drug Market in Europe (2020-2030)
11.1 Liver Cancer Drug Market Size
11.2 Liver Cancer Drug Market by End Use
11.3 Competition by Players/Suppliers
11.4 Liver Cancer Drug Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Liver Cancer Drug Market in MEA (2020-2030)
12.1 Liver Cancer Drug Market Size
12.2 Liver Cancer Drug Market by End Use
12.3 Competition by Players/Suppliers
12.4 Liver Cancer Drug Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Liver Cancer Drug Market (2020-2025)
13.1 Liver Cancer Drug Market Size
13.2 Liver Cancer Drug Market by End Use
13.3 Competition by Players/Suppliers
13.4 Liver Cancer Drug Market Size by Type
Chapter 14 Global Liver Cancer Drug Market Forecast (2025-2030)
14.1 Liver Cancer Drug Market Size Forecast
14.2 Liver Cancer Drug Application Forecast
14.3 Competition by Players/Suppliers
14.4 Liver Cancer Drug Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Bayer
15.1.1 Company Profile
15.1.2 Main Business and Liver Cancer Drug Information
15.1.3 SWOT Analysis of Bayer
15.1.4 Bayer Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
15.2 Roche
15.2.1 Company Profile
15.2.2 Main Business and Liver Cancer Drug Information
15.2.3 SWOT Analysis of Roche
15.2.4 Roche Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
15.3 Merck
15.3.1 Company Profile
15.3.2 Main Business and Liver Cancer Drug Information
15.3.3 SWOT Analysis of Merck
15.3.4 Merck Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
15.4 Bristol-Myers Squibb
15.4.1 Company Profile
15.4.2 Main Business and Liver Cancer Drug Information
15.4.3 SWOT Analysis of Bristol-Myers Squibb
15.4.4 Bristol-Myers Squibb Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
15.5 Eisai
15.5.1 Company Profile
15.5.2 Main Business and Liver Cancer Drug Information
15.5.3 SWOT Analysis of Eisai
15.5.4 Eisai Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
15.6 Exelixis
15.6.1 Company Profile
15.6.2 Main Business and Liver Cancer Drug Information
15.6.3 SWOT Analysis of Exelixis
15.6.4 Exelixis Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
15.7 AstraZeneca
15.7.1 Company Profile
15.7.2 Main Business and Liver Cancer Drug Information
15.7.3 SWOT Analysis of AstraZeneca
15.7.4 AstraZeneca Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
15.8 Novartis
15.8.1 Company Profile
15.8.2 Main Business and Liver Cancer Drug Information
15.8.3 SWOT Analysis of Novartis
15.8.4 Novartis Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
15.9 Pfizer
15.9.1 Company Profile
15.9.2 Main Business and Liver Cancer Drug Information
15.9.3 SWOT Analysis of Pfizer
15.9.4 Pfizer Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
15.10 Eli Lilly
15.10.1 Company Profile
15.10.2 Main Business and Liver Cancer Drug Information
15.10.3 SWOT Analysis of Eli Lilly
15.10.4 Eli Lilly Liver Cancer Drug Revenue, Gross Margin and Market Share (2020-2025)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Liver Cancer Drug Report
Table Data Sources of Liver Cancer Drug Report
Table Major Assumptions of Liver Cancer Drug Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Liver Cancer Drug Picture
Table Liver Cancer Drug Classification
Table Liver Cancer Drug Applications
Table Drivers of Liver Cancer Drug Market
Table Restraints of Liver Cancer Drug Market
Table Opportunities of Liver Cancer Drug Market
Table Threats of Liver Cancer Drug Market
Table COVID-19 Impact For Liver Cancer Drug Market
Table Raw Materials Suppliers
Table Different Production Methods of Liver Cancer Drug
Table Cost Structure Analysis of Liver Cancer Drug
Table Key End Users
Table Latest News of Liver Cancer Drug Market
Table Merger and Acquisition
Table Planned/Future Project of Liver Cancer Drug Market
Table Policy of Liver Cancer Drug Market
Table 2020-2030 North America Liver Cancer Drug Market Size
Figure 2020-2030 North America Liver Cancer Drug Market Size and CAGR
Table 2020-2030 North America Liver Cancer Drug Market Size by Application
Table 2020-2025 North America Liver Cancer Drug Key Players Revenue
Table 2020-2025 North America Liver Cancer Drug Key Players Market Share
Table 2020-2030 North America Liver Cancer Drug Market Size by Type
Table 2020-2030 United States Liver Cancer Drug Market Size
Table 2020-2030 Canada Liver Cancer Drug Market Size
Table 2020-2030 Mexico Liver Cancer Drug Market Size
Table 2020-2030 South America Liver Cancer Drug Market Size
Figure 2020-2030 South America Liver Cancer Drug Market Size and CAGR
Table 2020-2030 South America Liver Cancer Drug Market Size by Application
Table 2020-2025 South America Liver Cancer Drug Key Players Revenue
Table 2020-2025 South America Liver Cancer Drug Key Players Market Share
Table 2020-2030 South America Liver Cancer Drug Market Size by Type
Table 2020-2030 Brazil Liver Cancer Drug Market Size
Table 2020-2030 Argentina Liver Cancer Drug Market Size
Table 2020-2030 Chile Liver Cancer Drug Market Size
Table 2020-2030 Peru Liver Cancer Drug Market Size
Table 2020-2030 Asia & Pacific Liver Cancer Drug Market Size
Figure 2020-2030 Asia & Pacific Liver Cancer Drug Market Size and CAGR
Table 2020-2030 Asia & Pacific Liver Cancer Drug Market Size by Application
Table 2020-2025 Asia & Pacific Liver Cancer Drug Key Players Revenue
Table 2020-2025 Asia & Pacific Liver Cancer Drug Key Players Market Share
Table 2020-2030 Asia & Pacific Liver Cancer Drug Market Size by Type
Table 2020-2030 China Liver Cancer Drug Market Size
Table 2020-2030 India Liver Cancer Drug Market Size
Table 2020-2030 Japan Liver Cancer Drug Market Size
Table 2020-2030 South Korea Liver Cancer Drug Market Size
Table 2020-2030 Southeast Asia Liver Cancer Drug Market Size
Table 2020-2030 Australia Liver Cancer Drug Market Size
Table 2020-2030 Europe Liver Cancer Drug Market Size
Figure 2020-2030 Europe Liver Cancer Drug Market Size and CAGR
Table 2020-2030 Europe Liver Cancer Drug Market Size by Application
Table 2020-2025 Europe Liver Cancer Drug Key Players Revenue
Table 2020-2025 Europe Liver Cancer Drug Key Players Market Share
Table 2020-2030 Europe Liver Cancer Drug Market Size by Type
Table 2020-2030 Germany Liver Cancer Drug Market Size
Table 2020-2030 France Liver Cancer Drug Market Size
Table 2020-2030 United Kingdom Liver Cancer Drug Market Size
Table 2020-2030 Italy Liver Cancer Drug Market Size
Table 2020-2030 Spain Liver Cancer Drug Market Size
Table 2020-2030 Belgium Liver Cancer Drug Market Size
Table 2020-2030 Netherlands Liver Cancer Drug Market Size
Table 2020-2030 Austria Liver Cancer Drug Market Size
Table 2020-2030 Poland Liver Cancer Drug Market Size
Table 2020-2030 Russia Liver Cancer Drug Market Size
Table 2020-2030 MEA Liver Cancer Drug Market Size
Figure 2020-2030 MEA Liver Cancer Drug Market Size and CAGR
Table 2020-2030 MEA Liver Cancer Drug Market Size by Application
Table 2020-2025 MEA Liver Cancer Drug Key Players Revenue
Table 2020-2025 MEA Liver Cancer Drug Key Players Market Share
Table 2020-2030 MEA Liver Cancer Drug Market Size by Type
Table 2020-2030 Egypt Liver Cancer Drug Market Size
Table 2020-2030 Israel Liver Cancer Drug Market Size
Table 2020-2030 South Africa Liver Cancer Drug Market Size
Table 2020-2030 Gulf Cooperation Council Countries Liver Cancer Drug Market Size
Table 2020-2030 Turkey Liver Cancer Drug Market Size
Table 2020-2025 Global Liver Cancer Drug Market Size by Region
Table 2020-2025 Global Liver Cancer Drug Market Size Share by Region
Table 2020-2025 Global Liver Cancer Drug Market Size by Application
Table 2020-2025 Global Liver Cancer Drug Market Share by Application
Table 2020-2025 Global Liver Cancer Drug Key Vendors Revenue
Figure 2020-2025 Global Liver Cancer Drug Market Size and Growth Rate
Table 2020-2025 Global Liver Cancer Drug Key Vendors Market Share
Table 2020-2025 Global Liver Cancer Drug Market Size by Type
Table 2020-2025 Global Liver Cancer Drug Market Share by Type
Table 2025-2030 Global Liver Cancer Drug Market Size by Region
Table 2025-2030 Global Liver Cancer Drug Market Size Share by Region
Table 2025-2030 Global Liver Cancer Drug Market Size by Application
Table 2025-2030 Global Liver Cancer Drug Market Share by Application
Table 2025-2030 Global Liver Cancer Drug Key Vendors Revenue
Figure 2025-2030 Global Liver Cancer Drug Market Size and Growth Rate
Table 2025-2030 Global Liver Cancer Drug Key Vendors Market Share
Table 2025-2030 Global Liver Cancer Drug Market Size by Type
Table 2025-2030 Liver Cancer Drug Global Market Share by Type

Companies Mentioned

  • Bayer
  • Roche
  • Merck
  • Bristol-Myers Squibb
  • Eisai
  • Exelixis
  • AstraZeneca
  • Novartis
  • Pfizer
  • Eli Lilly

Related Topics

Related Reports

Liver Cancer Drugs Market by Drug Type, Mechanism Of Action, Treatment Line, Administration Route, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Liver Cancer Drugs Market by Drug Type, Mechanism Of Action, Treatment Line, Administration Route, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028 - Product Image

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028

  • Report
  • 88 Pages
  • United States
From
Liver Cancer Drugs - Global Strategic Business Report - Product Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • 277 Pages
  • Global
From
Advanced Liver Cancer Market Report 2025 - Product Image

Advanced Liver Cancer Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Liver Cancer Drug Market Size, Share & Trends Analysis Report by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Type (Hepatocellular Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Region, and Segment Forecasts 2025-2030 - Product Image

Liver Cancer Drug Market Size, Share & Trends Analysis Report by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Type (Hepatocellular Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Region, and Segment Forecasts 2025-2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.